Daiichi Sankyo has decided to sell its majority stake in Ranbaxy Laboratories to India’s Sun Pharmaceutical Industries as part of an all-stock deal that values the company at approximately US$4 B, including debt, and which will create the world’s fifth-largest speciality generics manufacturer. On completion of the acquisition, Sun Pharma’s priority will be to resolve the myriad of regulatory problems ongoing at Ranbaxy, including import bans imposed by the US FDA on four of the company’s manufacturing facilities in India. An Indian court has temporarily halted the merger, however, until an allegation of insider trading is investigated.